Clinical application of alpha1 adrenoceptor antagonist Naftopidil to the treatment of chronic non-bacterial prostatitis.
- Author:
Xin LI
1
;
Ning-chen LI
;
Qiang DING
;
Song-liang CAI
;
Hong-xu HUO
;
Shao-yan CHEN
;
Xiao-jian GU
;
Shi-ping CHEN
;
Yan-qun NA
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adrenergic alpha-Antagonists; therapeutic use; Adult; Chronic Disease; Humans; Male; Middle Aged; Naphthalenes; therapeutic use; Piperazines; therapeutic use; Prostatitis; drug therapy
- From:National Journal of Andrology 2006;12(3):234-239
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the efficacy and safety of alpha1 adrenoceptor antagonist Naftopidil in the treatment of chronic non-bacterial prostatitis.
METHODSAn opened, self-controlled, multicentral clinical trial was conducted. One hundred and six cases of patients who had been diagnosed as chronic non-bacterial prostatitis (NBP) were treated with Naftopidil (25 mg once a day) for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the WBC in the examination of prostatic secretion (EPS) after the treatment.
RESULTSAfter 4 weeks therapy, 105 cases were evaluable. After treatment, NIH-CPSI total score were averagely decreased 12.0 points (P <0.001), symptom score 7.9 points (P <0.001) and QOL score 4.1 points (P <0.001). There was a statistically significant difference in WBC count ([(15.2 +/- 15.1)/HP vs (9.5 +/- 12.0)/HP, P < 0.01] and max flow rate(MFR) [(19.2 +/- 4.8) ml/s vs (22.7 +/- 4.9) ml/s, P < 0.01]. The total effective rate were 84.8% in the whole group. The clinical adverse rate was 3.81%, including 3 cases of mild dizziness and 1 case of mild inappetence.
CONCLUSIONalpha1 adrenoceptor antagonist Naftopidil is effective and safe for the treatment of chronic non-bacterial prostatitis.
